Clinical Trials

CBD Reduces Overall Anxiety in Advanced Breast Cancer Patients Study Finds
Research & Development CBD Reduces Overall Anxiety in Advanced Breast Cancer Patients Study Finds

The effectiveness of cannabidiol (CBD) in reducing anxiety among patients with advanced breast cancer has become an intriguing subject for researchers, especially in the context of scan-related anxiety. A recent study conducted by researchers from the Dana-Farber Cancer Institute and Mass General

New Molecular Insights into Rett Syndrome from MeCP2 Gene Study
Research & Development New Molecular Insights into Rett Syndrome from MeCP2 Gene Study

Rett syndrome is a severe neurological disorder primarily affecting young girls, leading to significant cognitive, motor, and communication impairments. The disorder is linked to mutations in the MeCP2 gene, which encodes the methyl-CpG binding protein 2 (MeCP2). Researchers have long sought to

Is Ocaliva Still Safe for PBC Patients Amid Rising Liver Injury Cases?
Research & Development Is Ocaliva Still Safe for PBC Patients Amid Rising Liver Injury Cases?

A drug initially celebrated for its potential in treating a rare liver disease has come under scrutiny following alarming safety findings. Ocaliva, developed by Intercept Pharmaceuticals and now under Alfasigma's ownership, was initially viewed as a breakthrough treatment for primary biliary

NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK
Research & Development NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK

The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European specialty

NICE Recommends AstraZeneca's Imfinzi with Chemo for Resectable NSCLC
Research & Development NICE Recommends AstraZeneca's Imfinzi with Chemo for Resectable NSCLC

The recent endorsement by the National Institute for Health and Care Excellence (NICE) to utilize AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy as a treatment for adults with resectable non-small cell lung cancer (NSCLC) marks a significant milestone in cancer care. This

Can POLB 001 Revolutionize CRS Treatment in Cancer Immunotherapy?
Research & Development Can POLB 001 Revolutionize CRS Treatment in Cancer Immunotherapy?

In a significant breakthrough, Poolbeg Pharma announced positive pre-clinical study results for their drug POLB 001, presented at the 66th American Society of Hematology (ASH) Annual Meeting. The study focused on the drug's potential to prevent Cytokine Release Syndrome (CRS), a frequently observed

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later